FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.
What happened
FDA reviewed Zealthy's website in August 2025 and found it offered compounded drug products, including semaglutide. FDA said statements on the site implied the compounded semaglutide was the same as FDA-approved Wegovy and Ozempic, when compounded products are not FDA-approved. FDA called the claims false or misleading and the products misbranded.
What FDA found
FDA says website statements falsely implied that Zealthy's compounded semaglutide is the same as FDA-approved Wegovy and Ozempic.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says a compounded drug is misbranded if its advertising or promotion is false or misleading.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]FDA says the misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA says receiving or delivering misbranded drugs in interstate commerce is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA asks Zealthy to take immediate action, including stopping the cited claims, and to respond in writing within 15 working days describing steps taken and how it will prevent recurrence. If it cannot complete the matter in that time, it must explain the delay and give a completion date.
Who should pay attention
- telehealth platforms selling compounded GLP-1 drugs
- compounding pharmacies that supply semaglutide
- marketers making brand-comparison claims for compounded drugs
This is a summary. Read the original letter on fda.gov.